Cardiogenic Shock Clinical Trial
— SPECKLE-ECMOOfficial title:
Evaluation of Speckle Tracking Parameters as Predictors of Successful VA ECMO Weaning Procedure. A Prospective Observational Pilot Study.
NCT number | NCT03532529 |
Other study ID # | 241001 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | November 28, 2018 |
Est. completion date | November 28, 2019 |
Verified date | December 2018 |
Source | Royal Brompton & Harefield NHS Foundation Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Purpose of this study is to assess whether measurements obtained through speckle tracking (LV
longitudinal and circumferential strain, RV longitudinal strain) can give additional
information in identifying patients who develop adverse outcomes 30 days post successfully
weaning from VA ECMO (liberation not for palliation). It is a prospective observational
non-blinded pilot study.
In order to achieve this purpose, speckle tracking analysis will be performed on the recorded
images of the transoesophageal echocardiogram performed during the last VA ECMO weaning study
of patients defined ready for VA ECMO liberation. VA ECMO liberation will be based according
to LVOT VTI increase and clinical judgment during patients' VA ECMO weaning study. It will be
assessed whether the population experiencing the outcomes of interest (death within 30 days
from VA ECMO liberation, hospital admission for a new episode of cardiogenic shock or heart
failure within 30 days from VA ECMO liberation, need for new mechanical circulatory support
within 30 days from VA ECMO liberation) and the population not experiencing these outcomes
have different values of strain (LV longitudinal and circumferential and RV longitudinal
strain) during the weaning study.
Status | Recruiting |
Enrollment | 24 |
Est. completion date | November 28, 2019 |
Est. primary completion date | November 28, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - 18 to 60 years. - Receiving VA ECMO mechanical circulatory support for cardiogenic shock and planning to undergo an echocardiogram as part of a VA ECMO weaning study. - Informed consent for study participation provided by the patient (where able) or personal consultee (where the patient is unable to provide consent) or nominated consultee (where the patient is unable to provide consent and no personal consultee is available). Exclusion Criteria: - Contraindication to transoesophageal echocardiography. - Patients who are expected to require heart transplantation, LVAD or biventricular VAD within 30 days from admission. - Patients who are not expected to survive weaning from VA ECMO (liberation from VA ECMO exclusively for purpose of palliation). - Contemporary presence of Impella device during VA ECMO weaning study. - Patients in atrial fibrillation or in a different rhythm from sinus at the moment of VA ECMO weaning study. - Patient's LVOT VTI is less than 10cm at any stage of VA ECMO weaning study and/or LVOT VTI is lower at the lowest achieved blood flow than it was at baseline (LVOT VTI criterion). |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Royal Brompton Hospital and Harefield NHS Foundation Trust | London |
Lead Sponsor | Collaborator |
---|---|
Royal Brompton & Harefield NHS Foundation Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the composite outcome | the composite outcome including the following outcomes of interest: death within 30 days from VA ECMO liberation the necessity of new Mechanical Circulatory Support (VA-ECMO, Impella, LVAD) within 30 days from VA ECMO liberation o Whether after VA ECMO liberation the patient still needs IABP or a RVAD support, this situation is not considered necessity of new Mechanical Circulatory Support. A necessity of new Mechanical Circulatory Support is defined when IABP or RVAD or VA ECMO or Impella are needed again after their removal heart transplantation within 30 days from VA ECMO liberation |
within 30 days from VA ECMO liberation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03283995 -
Hemodynamic Assessment in Cardiogenic Shock Regarding the Etiology
|
||
Active, not recruiting |
NCT04325035 -
The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock
|
Phase 2 | |
Active, not recruiting |
NCT05100836 -
SURPASS Impella 5.5 Study
|
||
Not yet recruiting |
NCT05106491 -
Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients
|
N/A | |
Completed |
NCT02301819 -
ExtraCorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock
|
N/A | |
Completed |
NCT01367743 -
Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock
|
Phase 4 | |
Recruiting |
NCT05728359 -
Genomic Determinants of Outcome in Cardiogenic Shock
|
||
Recruiting |
NCT05699005 -
Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO
|
Phase 1 | |
Not yet recruiting |
NCT06338345 -
Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients
|
N/A | |
Completed |
NCT03436641 -
Microcirculation in Cardiogenic Shock
|
||
Recruiting |
NCT03313687 -
SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK
|
||
Recruiting |
NCT05506449 -
The RECOVER IV Trial
|
N/A | |
Completed |
NCT04144660 -
"Treatment Use of ECMO In Pregnancy or Peripartum Patient."
|
||
Completed |
NCT04548739 -
Cerebral Autoregulation in Pediatric ECMO (ECMOX 2)
|
||
Recruiting |
NCT04141410 -
Global Longitudinal Strain Assessment in Cardiogenic Shock During Sepsis
|
||
Not yet recruiting |
NCT05879276 -
Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.
|
Phase 3 | |
Enrolling by invitation |
NCT05570864 -
Score TO Predict SHOCK - STOP SHOCK
|
||
Completed |
NCT02591771 -
Study of Multistep Pharmacological and Invasive Management for Cardiogenic Shock
|
Phase 2 | |
Terminated |
NCT02279979 -
Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial
|
N/A | |
Completed |
NCT01374867 -
CardShock Study and Registry
|
N/A |